It's becoming a common theme that MULTI-TARGETED kinase inhibitors may be LESS effective than a single-targeted compound which you can really use at high doses (and then stack other drugs on top of that drug to really slam the cancer - another compound targeting a different pathway at a much higher dose than you would get with a junk multi-targeted compound).
These crappy multi-targeted approaches essentially hit so many targets that you can't dose a patient at high enough levels for it not to be toxic.
Look at the junk Exelixis has been building for years now. All multi-targeted me-too crap. And they have produced nothing but meager results, at best.
Market Data 
Markets 
AI
